Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade | DelveInsight
I-MAB - American Depositary Shares (IMAB)
Company Research
Source: PR Newswire
The bispecific antibodies in oncology market is anticipated to experience substantial growth in the coming years. This growth is driven by the rising incidence of ALL, DLBCL, NSCLC, BTC, and others, technological advancements, increasing regulatory approvals, strategic collaborations, and high market demand. Additionally, the expected launch of emerging bispecific antibodies in oncology, such as Givastomig, Volrustomig, BNT327, Acasunlimab, Rilvegostomig, CTX-009, IBI363, REGN5459, CA-170, Ivonescimab, and others, will further propel the market.LAS VEGAS, Sept. 15, 2025 /PRNewswire/ -- DelveInsight's Bispecific Antibodies in Oncology Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Acute Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer, Small-cell
Show less
Read more
Impact Snapshot
Event Time:
IMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMAB alerts
High impacting I-MAB - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMAB
News
- Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye DisordersPR Newswire
- I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech PlatformPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMABPR Newswire
- I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- I-Mab (NASDAQ:IMAB) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
IMAB
Sec Filings
- 10/31/25 - Form 6-K
- 10/30/25 - Form 6-K
- 10/30/25 - Form 424B3
- IMAB's page on the SEC website